These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 35750540)

  • 21. The estimated impact of natural immunity on the effectiveness of human papillomavirus vaccination.
    Matthijsse SM; Hontelez JAC; Naber SK; van Rosmalen J; Rozemeijer K; Penning C; Bakker R; van Ballegooijen M; de Kok IMCM; de Vlas SJ
    Vaccine; 2015 Oct; 33(41):5357-5364. PubMed ID: 26348405
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Human papillomavirus vaccine uptake in boys and girls in a school-based vaccine delivery program in Prince Edward Island, Canada.
    McClure CA; MacSwain MA; Morrison H; Sanford CJ
    Vaccine; 2015 Apr; 33(15):1786-90. PubMed ID: 25731789
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Parental acceptability of HPV vaccination for boys and girls aged 9-13 years in China - A population-based study.
    Wang Z; Wang J; Fang Y; Gross DL; Wong MCS; Wong ELY; Lau JTF
    Vaccine; 2018 May; 36(19):2657-2665. PubMed ID: 29606519
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assessing the cost-effectiveness of HPV vaccination strategies for adolescent girls and boys in the UK.
    Datta S; Pink J; Medley GF; Petrou S; Staniszewska S; Underwood M; Sonnenberg P; Keeling MJ
    BMC Infect Dis; 2019 Jun; 19(1):552. PubMed ID: 31234784
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Municipally sponsored human papillomavirus (HPV) vaccination of boys in Slovenia: the first 4 years.
    Troha M; Šterbenc A; Mlaker M; Poljak M
    Acta Dermatovenerol Alp Pannonica Adriat; 2019 Jun; 28(2):71-74. PubMed ID: 31233170
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety of the AS04-adjuvanted human papillomavirus (HPV)-16/18 vaccine in adolescents aged 12-15 years: end-of-study results from a community-randomized study up to 6.5 years.
    Bi D; Apter D; Eriksson T; Hokkanen M; Zima J; Damaso S; Soila M; Dubin G; Lehtinen M; Struyf F
    Hum Vaccin Immunother; 2020 Jun; 16(6):1392-1403. PubMed ID: 31829767
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HPV.edu study protocol: a cluster randomised controlled evaluation of education, decisional support and logistical strategies in school-based human papillomavirus (HPV) vaccination of adolescents.
    Skinner SR; Davies C; Cooper S; Stoney T; Marshall H; Jones J; Collins J; Hutton H; Parrella A; Zimet G; Regan DG; Whyte P; Brotherton JM; Richmond P; McCaffrey K; Garland SM; Leask J; Kang M; Braunack-Mayer A; Kaldor J; McGeechan K
    BMC Public Health; 2015 Sep; 15():896. PubMed ID: 26373926
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Trends in Human Papillomavirus Vaccination in Commercially Insured Children in the United States.
    Chen ST; Huybrechts KF; Bateman BT; Hernández-Díaz S
    Pediatrics; 2020 Oct; 146(4):. PubMed ID: 32928985
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Human papillomavirus (HPV) vaccination coverage in Brazil: spatial and age cohort heterogeneity.
    Moura LL; Codeço CT; Luz PM
    Rev Bras Epidemiol; 2020; 24():e210001. PubMed ID: 33331411
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Provider factors associated with disparities in human papillomavirus vaccination among low-income 9- to 17-year-old girls.
    Vadaparampil ST; Staras SA; Malo TL; Eddleton KZ; Christie J; Rodriguez M; Giuliano AR; Shenkman EA
    Cancer; 2013 Feb; 119(3):621-8. PubMed ID: 23341308
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Interest of a geostatistical approach to analyze the geographical disparities in human papillomavirus vaccine coverage in France].
    Ribassin-Majed L; Pereira M; Magneron C; Levy-Bachelot L; Fagherazzi G; Baldauf JJ; Raude J
    Rev Epidemiol Sante Publique; 2021 Nov; 69(6):321-328. PubMed ID: 34728109
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HPV vaccination coverage in three districts in Zimbabwe following national introduction of 0,12 month schedule among 10 to 14 year old girls.
    LaMontagne DS; Manangazira P; Marembo J; Chigodo C; Zvamashakwe C; Tshuma E; Marima E; Chindedza K; Ndlela E; Mooney J
    Vaccine; 2022 Mar; 40 Suppl 1():A58-A66. PubMed ID: 34275674
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inter-state variation in human papilloma virus vaccine coverage among adolescent girls in the 50 US states, 2007.
    Kramer MR; Dunlop AL
    Matern Child Health J; 2012 Apr; 16 Suppl 1():S102-10. PubMed ID: 22453332
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Estimate of global human papillomavirus vaccination coverage: analysis of country-level indicators.
    Spayne J; Hesketh T
    BMJ Open; 2021 Sep; 11(9):e052016. PubMed ID: 34475188
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Attitudes, Knowledge and Factors Associated with Human Papillomavirus (HPV) Vaccine Uptake in Adolescent Girls and Young Women in Victoria, Australia.
    Tung IL; Machalek DA; Garland SM
    PLoS One; 2016; 11(8):e0161846. PubMed ID: 27564213
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The contagious nature of a vaccine scare: How the introduction of HPV vaccination lifted and eroded MMR vaccination in Denmark.
    Gørtz M; Brewer NT; Hansen PR; Ejrnæs M
    Vaccine; 2020 Jun; 38(28):4432-4439. PubMed ID: 32418796
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of human papilloma virus (HPV) vaccination strategies and vaccination coverage in adolescent girls worldwide.
    Owsianka B; Gańczak M
    Przegl Epidemiol; 2015; 69(1):53-8, 151-5. PubMed ID: 25862448
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The projected timeframe until cervical cancer elimination in Australia: a modelling study.
    Hall MT; Simms KT; Lew JB; Smith MA; Brotherton JM; Saville M; Frazer IH; Canfell K
    Lancet Public Health; 2019 Jan; 4(1):e19-e27. PubMed ID: 30291040
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Is expanding HPV vaccination programs to include school-aged boys likely to be value-for-money: a cost-utility analysis in a country with an existing school-girl program.
    Pearson AL; Kvizhinadze G; Wilson N; Smith M; Canfell K; Blakely T
    BMC Infect Dis; 2014 Jun; 14():351. PubMed ID: 24965837
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Assessing HPV vaccine coverage in Australia by geography and socioeconomic status: are we protecting those most at risk?
    Barbaro B; Brotherton JM
    Aust N Z J Public Health; 2014 Oct; 38(5):419-23. PubMed ID: 24962721
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.